Please login to the form below

Not currently logged in
Email:
Password:

Amgen’s Joseph Turgeon joins Spectrum as SVP sales and commercial operations

Joins fellow former Amgen employee Ken Keller

Spectrum Pharmaceuticals has appointed former Amgen executive Joseph Turgeon to senior VP sales and commercial operations.

In his new role, Turgeon will have responsibility for the commercialisation and sales of Spectrum's complete portfolio, which includes cancer treatments Fusilev (levoleucovorin), Folotyn (pralatrexate injection) and Zevalin (ibritumomab tiuxetan).

Turgeon has strong pedigree in the oncology market, having most recently served as VP sales, oncology at Amgen, where he led the launch of four new drugs and oversaw an increase in annual revenue from $2bn to more than $6bn.

He is the second major figure to move from Amgen to Spectrum in recent months following the appointment of Ken Keller as chief operating officer in September this year.

”The addition of Mr Turgeon following appointment of Mr Keller earlier this year is part of a planned strategy for expedited growth of Spectrum Pharmaceuticals,” Rajesh Shrotriya, chair, president and CEO of Spectrum Pharmaceuticals.

“With three anticancer drugs on the market now bringing nearly $300m in pro forma revenue and nearly ten drugs in clinical development, we are committed to strong growth in the next five years.”

In addition to Turgeon's appointment, Spectrum also announced that the company's chief commercial officer Jim Shields is to retire due to health reasons. He will continue to serve Spectrum in an advisory role.

31st October 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics